Lung cancer is the leading cause of cancer-related deaths in the world. In this study, we investigated the combination of carboxyamidotriazole (CAI) and sorafenib in NSCLC in vitro and in vivo, to test whether CAI enhances the antitumor effects of sorafenib and reduces its side effects.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in the world and 5-year survival of lung cancer patients is approximate 4-17% along with differences in stage and region (Hirsch et al., 2016) . Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancers in worldwide (Jemal et al., 2011) . The most frequently used treatments for NSCLC are surgical, chemotherapy and radiotherapy. Unfortunately, when diagnosed, 2/3 of the patients are on an advanced and inoperable stage. Many of platinum-based regimens are first-line chemotherapies; Single-agent docetaxel, pemetrexed, and erlotinib are considered as second-line therapies. However, if patients fail to respond to conventional chemotherapies, the treatment options are limited (Langer et al., 2013) . Presented therapies have shown to be inadequate and novel strategies are urgently required.
Sorafenib is a multikinase inhibitor that blocks Raf kinase, platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptors (VEGFR). It was approved by FDA for the treatment of advanced renal cell carcinoma (RCC) and unresectable hepatocellular carcinoma (HCC) (Wilhelm et al., 2006) . Sorafenib has been confirmed activity in preclinical models of NSCLC (Wilhelm et al., 2004; Gridelli et al., 2007) , and it has also been under evaluation in several clinical trials (Ⅰ-Ⅲ phases) in advanced NSCLC patients (Clark et al., 2005; Moore et al., 2005; Blumenschein et al., 2009; Wakelee et al., 2012; Paz-Ares et al., 2015) . One limitation that hampers the use of sorafenib as a monotherapy is side effects, such as hand-foot syndrome, rash, diarrhea, hypertension and fatigue, which has been harassing 80% of patients receiving sorafenib treatment (Batchelor et al., 2007; Strumberg et al., 2007) . Most of the aforementioned side effects of sorafenib are dose-dependent, therefore reducing its dosage while This article has not been copyedited and formatted. The final version may differ from this version.
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5 keeping same therapeutic effect may need further investigation.
Carboxyamidotriazole (CAI) is a blocker of non-voltage dependent calcium channel, which shows anti-angiogenic, anti-proliferative and anti-metastatic properties in preclinical research.
CAI has been investigated under Phase I-III clinical trials in various solid tumors (Berlin et al., 1997; Kohn et al., 1997; Hussain et al., 2003; Dutcher et al., 2005; Johnson et al., 2008) . Although CAI exhibits mild anti-cancer properties in some of those clinical trials, the majority of toxicities noted were Grade I, which means CAI was generally well tolerated (Hussain et al., 2003; Desai et al., 2004; Dutcher et al., 2005; Mikkelsen et al., 2007) . In addition, CAI exhibited a protective role in treating cancer-associated cachexia by inhibiting muscle proteolysis and restraining inflammatory responses (Chen et al., 2017) , which implies CAI may synergize with other anti-cancer drug through limiting the weight loss induced by chemotherapy. In chronic myeloid leukemia cells, CAI was shown to reduce cell viability and induce apoptosis by a redox-mediated way (Alessandro et al., 2008; Corrado et al., 2011) . Our previous work showed that CAI synergized with 2-DG, a glycolysis inhibitor, in respect that CAI inhibited oxidative phosphorylation (OXPHOS) in cancer cells (Ju et al., 2016) . These data imply that CAI may perturb cell metabolism, damage mitochondrial function, elevate reactive-oxygen species (ROS) production, and finally induce cell death.
The transcription factor NANOG confers self-renewal and differentiation to cancer stem cells (CSCs), and it is often considered as a hallmarker of CSCs. Recently accumulated data show that the expression of NANOG in cancer cells can make it possess certain CSC properties such as This article has not been copyedited and formatted. The final version may differ from this version.
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6 self-renewal, tumorigenicity, metastasis and resistance to chemotherapy (Gong et al., 2015) .
Overexpression of NANOG in benign 293 cells contributed to malignant transformation, along with tumorigenesis, dramatically increasing clonogenicity, and promoting tumor growth in vivo (Lin et al., 2011) . In lung cancer patient, both NANOG mRNA and protein expressions in lung cancer tissues were much higher than that in patient-matched normal tissues (Du et al., 2013) . As to the signaling that NANOG perturbed within cells, Chen et al. show that in tumor-initiating stem-like cells (TICs), NANOG prevented mitochondrial ROS production and NANOG-silenced TICs produced much more ROS than control .
Objectives of our study were firstly to probe whether a combined therapy of CAI and sorafenib may allow a dose reduction of sorafenib and avoid of lessening effectiveness, then to investigate the mechanism by which the combination was exerting its action.
Materials and methods
Cell lines and reagents
Lewis lung carcinoma (LLC) was purchased from Shanghai Institute for Biological Sciences, CAS. A549 and NCI-H1975 (H1975) cells were purchased from Institute of Basic Medical Sciences, CAMS&PUMC. LLC cell was cultured in DMEM (high glucose). A549 cell was maintained in F-12K. H1975 was grown in RPMI 1640. All mediums were with supplement of 10% Fetal Bovine Serum (Gibco), 50 mg/mL penicillin, 100mg/mL streptomycin and L-glutamine.
Cells were maintained in a humidified atmosphere with 5% CO 2 at 37℃.
Carboxyamidotriazole was synthesized by the Institute of Materia Medica, Chinese Academy
This article has not been copyedited and formatted. The final version may differ from this version. and diluted with corresponding medium to the final concentration with DMSO concentration of 0.1%. For in vivo studies, compounds were dissolved in polyethylene glycol-400 (PEG400) (Sinopharm Chemical Reagent, Beijing, China).
Cell proliferation assay, combination index
Proliferations of cells for different concentrations after indicated time of treatment were assessed through Sulforhodamine B (SRB) method (Vichai et al., 2006) . DMSO was used as vehicle. Following treatment with CAI and/or sorafenib for indicated time period (24 h, 48 h and 72 h), cells in 96-well plates were fixed with 10% (wt/vol) trichloroacetic acid at 4℃ for 1h, then the plates were washed by slow-running water for 5 times and dried at room temperature. Next, the intracellular proteins were stained by 0.4% SRB for 20min and then the plates were washed five times with 1% (vol/vol) acetic acid. After adding 200 µL of 10 mM Tris base solution in each well, the absorbance of SRB can be detected at 515nm in a microplate reader. Combination indices (CIs) were calculated using CompuSyn software (ComboSyn Inc, Paramus, NJ, USA) (Chou et al., 1984; Chou, 2006) . According to Chou-Talalay, a CI <1 or >1 indicated synergism or antagonism, respectively.
Apoptosis and cell cycle analysis by flow cytometry
This article has not been copyedited and formatted. The final version may differ from this version. Following treatment with CAI and/or sorafenib for 48 h, cells were harvested and fixed in 75% ethanol at 4℃ for 18 h. After washing with cold PBS twice, DNA staining was performed using propidium iodide (0.05 mg/ml) and RNase (2 mg/ml) (Beyotime Biotechnology) at room temperature for 30 min. The cell cycle distributions were measured by FCM (excitation/ emission wavelength: 488 nm/617 nm). The distribution of cell cycle phases were calculated using ModFit LT software (Verity Software House, Topsham, ME, USA).
Determination of intracellular ROS level and mitochondrial membrane potential 
Immunohistochemistry staining
Tumor sections from C57 bearing LLC transplant model were baked at 60℃ for 20 min, deparaffinized with xylene and rehydrated in graded ethanol series. After antigen retrieval and endogenous peroxidase activity blocking, the slides were stained for NANOG (ab80892, Abcam; dilution 1:1000). Localization of specific reactivity was detected using a secondary antibody conjugated to peroxidase followed by observation with DAB substrate (Zhongshan Golden Bridge Biotechnology, China). Slides were counterstained with hematoxylin.
Total RNA extraction and RT (reverse transcription)-qPCR(quantitative PCR)
RNA was isolated from LLC cell using Pure RNA Extraction Kit (Bioteke corp., Beijing, China) and 2 μg of total RNA was used to synthesize cDNA with the TransScript First-Strand RT-qPCR reaction (25μl) contained 2μl of diluted cDNA, 12.5μl of 2×Maxima SYBR Green (Thermo Fisher Scientific Inc., Pittsburgh, USA). All reactions were performed using the following thermal cycle conditions: 94℃ for 2 min followed by 40 cycles of a two-step reaction, denaturation at 94℃ for 10s, annealing at 60℃for 30s, followed by a melting curve from 55 to 95℃
in 1 s increments of 0.5℃ to ensure amplification specificity. Transcript levels of the target genes were normalized to GAPDH.
Malondialdehyde (MDA) assay
Tumor tissues were homogenized and prepared for MDA assay according to the manufacturer's instructions in the Lipid Peroxidation MDA assay kit (Beyotimes, Nantong, China).
The MDA concentration of each sample was detected at 532 nm (450 nm as a control), by microplate reader (Synergy 4, Biotek).
Statistical analysis
All data were expressed as the mean±S.D. of three independent set of experiments unless otherwise indicated and analysed by Student's t-test or ANOVA followed by the Tukey's multiple comparison test. P-Values<0.05 were considered as statistically significant.
Results
Effects of sorafenib and CAI on LLC, A549 and H1975 NSCLC cell lines
This article has not been copyedited and formatted. The final version may differ from this version. To measure the response of NSCLC cells to sorafenib and/or CAI, we first performed cell proliferation assays. We incubated LLC, A549 and H1975 cell lines with the respective drugs and their combinations. Sorafenib at concentrations of 0.5, 1, 2.5, 5, 7.5, 10 μM and CAI at concentrations of 1, 2, 5, 10, 15, 20 μM and their combination were all applied. As shown in Fig 1, CAI, sorafenib and their combination led to a dramatically reduce cell proliferation, in a dose-dependent manner, in three cell lines investigated. It is noteworthy that the cytotoxicity effect of sorafenib as low as 1 μM in combination with CAI, was comparable to 10-15 μM sorafenib in single use in three cell lines and three time points. In order to do mathematical analysis, three cell lines were treated with different concentrations of CAI and sorafenib at a fixed ratio (2:1), using median effect analysis (Chou et al., 1984) . 
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14 cell, after the same treatments as that in LLC, the apoptotic cell percentages were 14.8% (CAI), 10.6% (Sorafenib) and 42.1% (Combination), respectively. Besides apoptosis, there was a portion of necrotic cells (Annexin V-/PI+) were observed (Fig 2A) .
To further confirm the induction of apoptosis by this combination, we analyzed cell extracts for expression of poly (ADP-ribose) polymerase (PARP) (an endogenous substrate of caspase-3 and -7), and cleaved caspase-3 which is associated in programmed cell death (Fig 2B, 2C) . (Fig 2A) . These results show that the combination of CAI and sorafenib synergistically induces apoptosis in vitro. The cell cycle analysis showed LLC and A549 cells treated with the CAI were arrested in G2/M phase and cells treated with sorafenib were arrested in G0/G1 phase. In addition, the combination group showed a significantly decrease in S phase and increase in both G0/G1 and G2/M phases (Fig 2D) .
Sorafenib and CAI increase DCFH-DA and MitoSOX oxidation suggesting increased intracellular ROS and provoke mitochondrial depolarization
Abnormal accumulation of intracellular ROS could induce oxidative stress in cancer cells and excessive ROS could directly attack DNA, protein, lipids, and other cellular components, eventually lead to cell apoptosis (Simon et al., 2000) . Previous studies showed that sorafenib or 
15 CAI alone could induce the generation of intracellular ROS both in vivo and in vitro (Corrado et al., 2011; Coriat et al., 2012) . Therefore we speculated that the synergistic effect on apoptosis of sorafenib and CAI might result in enhanced the abnormal level of ROS. We first utilized DCFH-DA as a probe and observed DCF fluorescence under a fluorescence microscope. In LLC and H1975 cell lines, ROS production were increased slightly in the presence of sorafenib or CAI, while it was provoked significantly in the combination group (Fig 3A) . Then we further observed enhanced fluorescence intensity upon increased MitoSOX oxidation after CAI, sorafenib or the combination treatment, suggesting that these interventions could increase mitochondrial ROS or superoxide at various degrees in LLC cell (Fig 3B) .
Since we found that mitochondrial released ROS, at least in part, contributed to the accumulation of the overall ROS in cells and high ROS level normally disrupted mitochondrial membrane potential (ΔΨ m ). In addition, mitochondrial depolarization is a distinctive feature of early stages of programmed cell death. Thus, we determined the changes in ΔΨ m by staining cells with dye JC-1. The treatment of CAI (10 μM) or sorafenib (5 μM) in LLC as monotherapy was slightly decreased ΔΨ m , while the combination group was dramatically damaged mitochondrial function as decreased 50% the ΔΨ m compared with DMSO control. Thus, these data revealed CAI and sorafenib induced ROS accumulation and sabotaged mitochondrial potential.
Sorafenib and CAI decreased the expression of NANOG in vitro
Several studies reveal that NANOG is not only a marker of stem cells, but also a key factor endowing cancer cells with certain stem cells characters such as metastasis, tumorigenicity, self-renewal, and drug-resistance (Gong et al., 2015) . To investigate the role of NANOG in CAI and/or sorafenib induced anti-cancer activity, we measured mRNA and protein levels of NANOG after exposing LLC cells with indicated treatment. As shown in Fig 4A, after 24 h treatment of CAI or sorafenib, NANOG mRNA level dropped slightly in single-agent groups compared with control, whereas the combination of CAI and sorafenib was more effective in restraining NANOG expression than as monotherapy (Fig 4A) . Similarly, the tendency was confirmed by Western-blot experiments (Fig 4B) .
To explore whether NANOG is involved in the accumulation of ROS after CAI and/or sorafenib treatment, we utilized basic fibroblast growth factor (bFGF), which is reported to stimulate NANOG expression in cancer cells (Shen et al., 2016) . In the present study, bFGF stimulated NANOG expression in LLC cell and promoted both LLC and A549 cells proliferation (Fig 4C, 4D) . In A549 and LLC cell lines, co-treatment of bFGF significantly reduced CAI and/or sorafenib mediated increase in intracellular ROS levels (Fig 4E, 4F) . Strikingly, in A549 cells, co-treatment of bFGF almost strangled the ability in increasing ROS of CAI or sorafenib as monotherapy (Fig 4G) . These results implied that NANOG expression was impaired by CAI in combination with sorafenib and the decrease of its expression was, at least partially, responsible for the accumulation of ROS. indicated drugs. As shown in Fig 5A, 5C , 40 ng ml -1 bFGF and 4 mM GSH partially reverted the effect of sorafenib and/or CAI on cell apoptosis. These data showed the production of ROS and the inhibition of NANOG are important upstream pathways of sorafenib and/or CAI induced cell apoptosis. In addition, in experiments with combination treatment of sorafenib and CAI increased amounts of necrotic cells (Annexin V-/PI+) were observed (Fig 5A, Fig 5C) . Combination treatment led to less tumor growth compared with single-drug treatment (Fig 6A) .
Sorafenib and CAI induced apoptosis in a ROS and NANOG-dependent manner in vitro
Combination of sorafenib and CAI exhibited synergistic antitumor activity in vivo
We then assessed the tumor weight to further verify the efficiency of this combination (Fig 6B) . In accordance with tumor volumes, the average tumor weights associated with PEG400, CAI, SFB-L, combination and SFB-H therapy were 4.77, 2.56, 2.14, 1.59 and 1.68 g, respectively. It is worthwhile noting that the dosage of sorafenib in combination group is 10mg kg -1 and in SFB-H group is 30mg kg -1 , and there is no statistical significance in the tumor weight between two groups (Fig 6B) .
To evaluate the side effect of mice in general, we monitored the weight of mice every day.
The average body weights arranging from high to low were PEG400 (29.58 g), CAI (29.14 g), combination (27.64 g), SFB-L (27.18 g) and SFB-H (26.66 g) (Fig 6D) . Although PEG400 group
This article has not been copyedited and formatted. The final version may differ from this version. was seemed to possess the highest body weight compared with other groups, the tumor weight in PEG400 group was much higher than others as mentioned before. So we calculated the carcass weight of each group to exclude the difference of tumor weights. As shown in Fig 6E, (Chen et al., 2017) , CAI group as well as combination group showed the potential to maintain the body weight of tumor-bearing mice compared with PEG400 group. It is noteworthy that the average carcass weight in combination group was significantly heavier than that in SFB-H group (Fig 6E) . Taken together, these data suggested that CAI not only synergized with sorafenib in the in vivo antitumor activity but also attenuated weight loss during cancer progression.
Sorafenib and CAI inhibit NANOG in vivo
As in vitro studies indicate that NANOG is a key mediator of CAI and sorafenib-induced cell death, we also investigated the expression of NANOG in vivo. We performed immunohistochemistry for NANOG expression in tumor sections after 29 days of treatment with sorafenib and/or CAI (Fig 7A) . The percentage of NANOG-stained tumor sections was significantly decreased in combination group as compared with vehicle or single agents. Using western blot analysis to test tumor lysis in each group, we further confirmed NANOG expression was decreased in combination group (Fig 7B) . In addition, H&E staining revealed that greater necrosis was observed in tumors following sorafenib and CAI treatment than in vehicle or single agents (Fig 7A) . The quantification of MDA is commonly applied as a marker for lipid 
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19 peroxidation and is often seen as the level of ROS-mediated injury. The level of MDA was increased in combination group compared with the other groups (Fig 7C) . Taken together, these data confirmed NANOG was downregulated after CAI and sorafenib treatment in vivo.
Discussion
We report here the synergistic anti-tumor effect of sorafenib and CAI in NSCLC both in vivo and in vitro. The underlying mechanisms of this effect are associated with down-regulation of NANOG and induction of apoptosis. The combination therapies induced apoptosis was mostly associated with mitochondrial related cell death, because the accumulation of mitochondrial ROS, upregulation of cleaved-caspase 3, and depolarization of mitochondrial.
NANOG has an important role in tumorigenesis, chemoresistance, relapse and metastasis.
Previous study showed that NANOG positive cancer stem cells (CSCs) were much more resistant to sorafenib than NANOG negative CSCs (Shan et al., 2012) . Here we found the combination of CAI and sorafenib could dramatically decrease the mRNA and protein levels of NANOG, which to some extent transferred NANOG-positive cells to a state of NANOG-negative cells. It might be a reason that in combination with CAI, NSCLC cells were more sensitive to sorafenib both in vivo and in vitro. To better understand the exact mechanism on how the combination group dramatically inhibits NANOG, the upstream signaling of NANOG perturbed by these two agents needs further explored.
Recently, it was shown that in TICs NANOG combines to the promoter of OXPHOS genes and restrains their expressions, led to quench the production of ROS . OXPHOS defect is a well known pivotal reason for the reduction of apoptosis in cancer cells (Yadav et al., This article has not been copyedited and formatted. The final version may differ from this version. display a considerable increase in tyrosine phosphorylation level than only one mutation in either L858R or T790M (Mulloy et al., 2007) . The combination regimen may not be able to counteract the aberrant activation of EGFR signaling. Mutations in the KRAS proto-oncogene are common aberrations and found in 10-30% of lung adenocarcinomas. These mutations lead to abnormal activation of KRAS signaling pathway that results in continuous cell proliferation and indicates poor prognostic of NSCLC. The combination of CAI and sorafenib conducts synergistic effect in cells regardless of KRAS mutations. These data imply that patients with KRAS mutations and without the L858R/T790M EGFR mutations will benefit from synergistic effect of CAI and sorafenib.
In conclusion, the combined therapy of CAI and sorafenib has synergistic effect in resisting NSCLC in vivo and in vitro, which may attribute to induction of apoptosis and inhibition of NANOG. The combination in vivo may allow a dose reduction of sorafenib and avoid of lessening effectiveness. Thus, our findings provide a novel strategy that expand the application of sorafenib and may raise a new choice for treatment of NSCLC.
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